BFSFs and FMV Under the Final Rule. February 22, 2016
|
|
- Thomas Gibbs
- 6 years ago
- Views:
Transcription
1 BFSFs and FMV Under the Final Rule February 22, 2016
2 Today s Speakers Chris Coburn Managing Director Huron Consulting Group ccobourn@huronconsultinggroup.com John Shakow Partner King & Spalding jshakow@kslaw.com
3 Topics General view towards BFSF/FMV, and increased scrutiny Key components of the Final Rule impacting BFSF/FMV 2
4 Abstract The Final Rule reasserts the importance of Service Fee and FMV evaluation, and reinforces the trend we have seen for increased scrutiny of BFSF determination, and documentation of your approach and rationale 3
5 The Multi-Part BFSF Test Is the service bona fide? Is the service itemized? Is the service actually performed? Is the service performed on behalf of the manufacturer? Would the manufacturer perform or otherwise contract for the service in the absence of the agreement? Is the service not passed on, in whole or in part, to a client or customer of the service-providing entity? Is the fee FMV for the services rendered? 4
6 Service Fees and FMV Manufacturers are affirmatively obliged to subject all service and administrative fees paid to AMP and BP eligible entities to the BFSF test and to document their conclusions at the time the agreement pay the fee is made. (with the possible exception of certain fees set out in the AMP definition, which we will discuss below) Note that the law does not make a qualitative judgement about the treatment of service or administrative fees. Al the law requires is that we subject these fees to the BFSF test. Passing the BFSF test does not make the fee legal, any more than failing the BFSF test makes the fee illegal. 5
7 Is BFSF/FMV a Compliance Driven Function in your organization? Make activities like BFSF reviews Compliance Functions, with involvement and oversight by Compliance and Legal Have policies in place for the process and decision making Take the decision point out of the hands of just the business and GP, ensure a comprehensive and collaborate review on each element of the multi-part test All service agreements and fee structures should be evaluated and documented as to whether they are BFSF Be able to demonstrate an independent and objective review and supporting documentation 6
8 The Final Rule Consistently References Reasonable Assumptions Can you defend your calculation methodologies and assumptions? Manufacturers must evaluate statutory and regulatory language for gaps and omissions and determine policies, approaches, and methodologies to address those gaps. The rationales should be evaluated independently of the financial impact, reviewed by legal counsel where appropriate, and well documented. Manufactures cannot universally revert to what may be perceived as Conservative, Conservative in one program may be viewed as Aggressive in another Example Treatment of a service fee as an excludable BFSF would drive all price points higher, which could be conservative for AMP with a potential higher URA, but also a higher ASP and higher PHS price, which could be perceived as aggressive ASP AMP URA PHS 7
9 Increased Focus on the Bona Fide nature of the service A recent Addendum to a Corporate Integrity Agreement notes that to ensure compliance with the Anti- Kickback Statute, pharmaceutical companies should establish and implement: A written review and approval process for all arrangements that includes at least the following a process for specifying the business need or business rationale for each service provided under the FFS arrangement and determining and documenting the fair market value of the remuneration specified in the FFS arrangement; 8
10 Evolving Approaches and Data Points Pros and Cons of Market Approach vs Cost Approach The industry approaches have evolved Pure Market approach may be skewed based upon type of company and percent of WAC approach Data Points have evolved and improved, cost approach more practical now Bifurcation of fees that exceed FMV a more common practice Important to consider multiple FMV approaches to alight on one (or several) that will produce the most accurate, defensible assessment Use of counsel and consultants such as Huron provide visibility across industry, visibility in to various data points, and an objective/independent view 9
11 Scrutiny will continue around BFSF treatment ASP, and now AMP Reimbursement metrics Creates a focus on BFSF Treatment 10
12 Key Aspects of the Final Rule Related to BFSF/FMV 11
13 Service Fees and FMV CMS continues to refuse to define FMV, that burden is on the manufacturer CMS requires each manufacturer to make FMV determinations (at least for those fees that otherwise pass the qualitative elements of the BFSF test), and to document the approach(es) used How should we interpret adequate documentation? The Final Rule suggested that evidence of rigorous negotiation with the service provider might suffice. CMS explicitly refused to create FMV safe harbors for price reporting and continued to refuse to adopt the OIG s GPO discount safe harbor. 12
14 BFSFs and Enumerated Fees The Medicaid statute lists distribution service fees, inventory management fees, product stocking allowances and fees associated with administrative services agreements and patient care programs in the BFSF provision of the AMP definition At issue is whether these fees are always BFSFs or if they must pass the multi-part regulatory BFSF test like all other service fees 13
15 BFSFs and Enumerated Fees (cont d) In several passages of the preamble, CMS could have addressed this question definitively, and it did not: [W]e believe that the examples provided in the [ACA] (including stocking allowances) are bona fide service fees and sufficient to provide manufacturers with a general sense of the types of such fees. Furthermore, fees, including but not limited to, distribution service fees, inventory management fees, product stocking allowances, fees associated with administrative service agreement and patient care programs (such as medication compliance programs and patient education programs) and other fees paid to GPOs that meet the definition of bona fide service fees as defined in this final rule, are excluded from the calculation of AMP and best price. Leaves open the possibility that these service arrangements could be automatically characterized as BFSFs and excluded (however, the more reasonable approach will likely be to apply the BFSF test to these fees) 14
16 Pass Through Pass Through Assumption Manufacturers may assume that there is not a pass through if they do not have notice or evidence of a pass through. So, what level of due diligence is appropriate? Perils of putting the question to service providers Back-end sharing of profits/extension of discounts may not constitute pass through. Manufacturers must make reasonable assumptions based on limited visibility. 15
17 Price Appreciation Credits The Final Rule makes plain that CMS understands price appreciation credits to be price adjustments, essentially negative lagged price concessions. BFSF and price appreciation payments may be netted for transactional convenience but the streams must be incorporated into pricing independently. 16
18 Expansion to the Territories Extending Medicaid to the Territories opens a wide array of challenges across the organization, including contracting relationships, pricing, Medicaid Best Price impact, data integrity, as well as the financial impact of extending the Medicaid Rebate. Has your organization evaluated the risks, and the ability to implement this change? The Final Rule extends Medicaid to five Territories: Puerto Rico, US Virgin Islands, Guam, American Samoa, and the Northern Mariana Islands. What are the service and/or administrative fees your company pays to entities in the Territories? FMV analysis of these fees may be different from, and more complicated than, that of your domestic fees. 17
19 5i AMP and Bona Fide Service Fees CMS wants to standardize the exclusion of BFSFs from all of its price types: Standard AMP, 5i AMP, Best Price and ASP Its reading of the statute, however, only permits the exclusion from AMP (of either type) of BFSFs paid to wholesalers or RCPs It therefore relies on some interpretive sleight-of-hand to exclude from the calculation of 5i AMP BFSFs paid to all the 5i-eligible entities that are not wholesalers or RCPs 18
20 5i AMP and Bona Fide Service Fees (cont d) [T]he exclusion of bona fide service fees cannot be expanded to apply to the entities other than wholesalers or retail community pharmacies, for purposes of the calculation of AMP for 5i drugs not generally dispensed through retail community pharmacies. However, we believe that the payments provided by manufacturers for such service fees may be excluded from AMP with regard to such 5i drugs, because such fees do not represent type of payments from, or discounts or rebates provided to, the [5i AMP eligible] entities. Therefore, such fees should not be included in the determination of [5i AMP]. 81 Fed Reg at
21 References Supporting Documents Huron Supporting Documents: 1. Final Rule Reading Guide 2. Huron Analysis and Initial Client Alert King & Spalding Supporting Documents: 1. Alert: 2. Federal Register TOC: 3. Redlined Final Regulations: 20
22 Innovative Life Science Strategies and Risk Mitigation. It s in our DNA. Thank You. Please contact us if you have any additional questions regarding this presentation. Chris Coburn Huron Consulting Group Managing Director ccobourn@huronconsultinggroup.com John Shakow King & Spalding Partner jshakow@kslaw.com
SETTING A STANDARD FOR GP COMPLIANCE
SETTING A STANDARD FOR GP COMPLIANCE CURRENT LANDSCAPE AND WHAT DOES GP COMPLIANCE LOOK LIKE? MAY 9, 2017 2017 HURON CONSULTING GROUP INC. SPEAKER INTRODUCTIONS Clay Willis Director T 404-825-3319 E cwillis@huronconsultinggroup.com
More informationImpact of the AMP Final Rule on Class of Trade & Contracting
Impact of the AMP Final Rule on Class of Trade & Contracting March 2016 Helping pharmaceutical manufacturers navigate the complex GP landscape Katie Lapins Disclaimer This presentation is provided for
More informationSpecialty Pharmacies. Ensuring Compliant Relationships. April 2017
Specialty Pharmacies Ensuring Compliant Relationships April 2017 Agenda I. Current climate II. Regulatory Overview III. Types of SPP relationships IV. Data purchase arrangements V. Fee for service arrangements
More informationNCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work
NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January 2016 The Centers for Medicare & Medicaid Services (CMS) recently issued a 658-page, oftendelayed, final rule on the
More informationModeling Price Increases and the Effects on Customer Segments
Modeling Price Increases and the Effects on Customer Segments CBI Medicaid Congress May 9, 2017 Jennifer English Director, Pricing, Contracting and Govt Programs, Insmed, Inc. Disclaimer The opinions and
More informationMarc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance
Marc Claussen, Chiesi USA, Director, Market Access Donna White, Chiesi USA, Sr. Director, Contracting and Compliance The views/observations expressed in this presentation are the personal views/observations
More informationMedicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary
Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary The Centers for Medicare & Medicaid Services (CMS) on February 2, 2012 published in the Federal Register a proposed rule
More informationContracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016
Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress October 20, 2016 Thomas Beimers Hogan Lovells Thomas.beimers@hoganlovells.com Sarah Franklin Covington
More informationBuilding a Strategic Plan for Physician Employment and Practice Acquisition
Building Practice Acquisition and Physician Employment Strategies that Will Last the Test of Time In a Changing Regulatory Environment David Lewis Vice President/Associate General Counsel LifePoint Hospitals
More informationHEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036
Curriculum Vitae HEATHER I. BATES Managing Director, BRG Health Analytics BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Direct: 202.480.2660 Cell: 202.641.1035 hbates@thinkbrg.com
More informationLegal Considerations for Patient Assistance Programs
Legal Considerations for Patient Assistance Programs March 6, 2014 Robert D. Clark Ober Kaler (202) 326-5039 Seth H. Lundy King & Spalding (202) 626-2924 S. Craig Holden Ober Kaler (410) 347-7322 Topics
More informationAugust 11, Submitted electronically via Regulations.gov
August 11, 2017 Submitted electronically via Regulations.gov Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1678-P PO Box 8013 Baltimore, MD 21244-1850
More informationGERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036
Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski
More informationNew York Institutes New Medicaid Drug Price Control Measures. State Budget Includes Medicaid Drug Expenditure Cap. FDA & Life Sciences Practice Group
FDA & Life Sciences Practice Group April 21, 2017 For more information, contact: John D. Shakow +1 202 626 5523 jshakow@kslaw.com Brian A. Bohnenkamp +1 202 626 5413 bbohnenkamp@kslaw.com Elizabeth F.
More informationHEALTH CARE FRAUD. EXPERT ANALYSIS HHS OIG Adopts New Anti-Kickback Safe Harbor and Civil Monetary Penalty Exceptions
Westlaw Journal HEALTH CARE FRAUD Litigation News and Analysis Legislation Regulation Expert Commentary VOLUME 22, ISSUE 7 / JANUARY 2017 EXPERT ANALYSIS HHS OIG Adopts New Anti-Kickback Safe Harbor and
More information340B Drug Program Compliance: Focus on Disproportionate Hospitals
340B Drug Program Compliance: Focus on Disproportionate Hospitals Part II: 340B Drug Program Compliance: Pharmacy Operations and the DSH January 29, 2014 1 Faculty Stephen J. Weiser, JD, LLM Director 312-403-4284
More informationManaging Financial Interests: The Anti Kickback Statute (AKS)
Managing Financial Interests: The Anti Kickback Statute (AKS) Board of Commissioners Meeting February 15, 2012 Presented by: Mic Sager, Compliance Officer Context: Business Transactions o Health Care is
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationHRSA Publishes Proposed Rule on the Calculation of 340B Ceiling Prices and Manufacturer Civil Monetary Penalties
FDA & Life Sciences Practice Group HRSA Publishes Proposed Rule on the Calculation of 340B Ceiling Prices and Manufacturer Civil Monetary Penalties Comments Due to HRSA by Monday, August 17, 2015 June
More informationSCHEMES, SCAMS AND FLIM-FLAMS: HOW THE DME SUPPLIER CAN RECOGNIZE FRAUD LANDMINES. Denise Leard, Esq Brown & Fortunato, P.C.
SCHEMES, SCAMS AND FLIM-FLAMS: HOW THE DME SUPPLIER CAN RECOGNIZE FRAUD LANDMINES Denise Leard, Esq. 2017 Brown & Fortunato, P.C. INTRODUCTION 2 INTRODUCTION When Medicare first came into existence, there
More informationOverview of Coverage of Drugs Under the Medicaid Medical Benefit
Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008 Amanda Bartelme Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Medical vs. Pharmacy
More informationBERKELEY RESEARCH GROUP. Executive Summary
Executive Summary Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees
More informationAvoiding Regulatory Land Mines in Commercial ACOs
Avoiding Regulatory Land Mines in Commercial ACOs Robert Belfort, Partner Healthcare Industry Martin Thompson, Partner Healthcare Industry Manatt, Phelps & Phillips, LLP September 30, 2014 Agenda 1 Antitrust
More informationApril 8, Dear Mr. Levinson,
April 8, 2019 Daniel Levinson Office of Inspector General Department for Health and Human Services Cohen Building, Room 5527 330 Independence Ave, SW Washington, DC 20201 Re: Fraud and Abuse; Removal of
More informationCOMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016
COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS Judd Katz JD MHA November 2016 Background information Patient Assistance Programs Copay Cards/Assistance Programs Reimbursement Support AGENDA
More informationMedicaid Prescription Drug Payment Reform
Medicaid Prescription Drug Payment Reform Spring 2006 NCSL Health Chairs Meeting John M. Coster, Ph.D., R.Ph. June 10, 2006 1 Community Retail Pharmacy In 2005, there were approximately 56,000 community
More informationREGULATORY ISSUES IMPACTING SUPPLY CHAIN
REGULATORY ISSUES IMPACTING SUPPLY CHAIN Michael Nachman Associate General Counsel John W. Jones, Jr. Partner Allan A. Thoen Partner April 27, 2017 2017 In House Counsel Conference Presenters: John W.
More informationPractical Considerations for Medical Practices Considering Converting Their Vascular Access Centers Into Medicare-Certified Ambulatory Surgery Centers
Practical Considerations for Medical Practices Considering Converting Their Vascular Access Centers Into Medicare-Certified Ambulatory Surgery Centers James B. Riley, Partner +1 312 750 8665 jriley@mcguirewoods.com
More informationFirst Tier Entity Attestation 2017 Medicare Advantage Organization (Sponsor) Compliance Program
10/19/2017 First Tier Entity Attestation 2017 As part of an effective compliance program, the Centers for Medicare and Medicaid Services (CMS) and other federal and state regulators require our Medicare
More informationPhysician Care: Physician Compensation. Presented by Albert R. Riviezzo, Esq. Fox Rothschild LLP Exton, PA
Physician Care: Physician Compensation Presented by Albert R. Riviezzo, Esq. Fox Rothschild LLP Exton, PA Overview Compensation trends for employed physicians Regulatory risks of physician compensation
More informationUpdate. The authors of this article are all consultants with Huron Consulting Group, which serves the continuum of life sciences organizations
Life Science Compliance Update REPRINTED FROM U.S. EDITION Volume 2.1 February 2016 Your Special Relationships Specialty Pharmacies and 5 Thoughtful Controls to Consider public advocates, and the media
More informationSubmitted electronically via to
April 8, 2019 Mr. Aaron Zajic Office of Inspector General U.S. Department of Health and Human Services Attention: OIG-0936-P Room 5527, Cohen Building 330 Independence Avenue, SW Washington, DC 20201 Submitted
More informationTrack III-A. Creating Relationships with Prescription Drug Plans and Managed Care Organizations
Track III-A Creating Relationships with Prescription Drug Plans and Managed Care Organizations David L. Ralston Legal Director Schering-Plough Corporation Part D is for Dollars Follow the money by tracing
More informationCOMPARING VERAGE SALES PRICES AND AVERAGE MANUFACTURER PRICES FOR MEDICARE PART B DRUGS: AN OVERVIEW OF 2013
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL A COMPARING VERAGE SALES PRICES AND AVERAGE MANUFACTURER PRICES FOR MEDICARE PART B DRUGS: AN OVERVIEW OF 2013 Suzanne Murrin Deputy
More informationRe: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs)
January 2, 2008 Reference No.: FASC08001 Kerry Weems Acting Administrator, Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200
More information2014 Lathrop & Gage LLP Lathrop & Gage LLP Lathrop & Gage LLP
Legal Issues for Physician Owned Implant Manufacturer/Distribution Companies (PODs) October 24, 2014 Randal L. Schultz, Esq. 10851 Mastin Blvd, Building 82, Suite 1000 Overland Park, KS 66210-1669 913.451.5192
More informationLIFEBLOOD OF THE SUCCESSFUL PHARMACY: MARKETING, JOINT VENTURES, AND ARRANGEMENTS WITH REFERRAL SOURCES WHILE REMAINING WITHIN LEGAL PARAMETERS
LIFEBLOOD OF THE SUCCESSFUL PHARMACY: MARKETING, JOINT VENTURES, AND ARRANGEMENTS WITH REFERRAL SOURCES WHILE REMAINING WITHIN LEGAL PARAMETERS Denise M. Leard, Esq. 2018 Brown & Fortunato, P.C. INTRODUCTION
More informationAaron Vandervelde Managing Director Berkeley Research Group
Aaron Vandervelde Managing Director Berkeley Research Group Statement re Interests Aaron Vandervelde provides services as an independent consultant concerning 340B matters to pharmaceutical manufacturers
More informationPREMIUM IMPACT OF REMOVING MANUFACTURER REBATES FROM THE MEDICARE PART D PROGRAM
PREMIUM IMPACT OF REMOVING MANUFACTURER REBATES FROM THE MEDICARE PART D PROGRAM July 6, 2018 RANDALL FITZPATRICK FSA, MAAA CHRIS CARLSON FSA, MAAA CONTENTS Executive Summary... 2 Data and Methodology...
More informationOut of bounds: CMS proposed rule for AMP under Medicaid
Out of bounds: CMS proposed rule for AMP under Medicaid Donna Lee Yesner, Stephen E Ruscus and Andrew D Ruskin Morgan Lewis www.practicallaw.com/8-518-2213 Medicaid, the US federal healthcare assistance
More informationHealth Reform Update: Focus on Prescription Drug Price Regulation
International Life Sciences Arbitration Health Industry Alert If you have questions or would like additional information on the material covered in this Alert, please contact the author: Joseph W. Metro
More informationRe: CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)
BY ELECTRONIC DELIVERY Mark McClellan, Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue, S.W.
More informationYOUR TRUST PLAN BENEFITS
YOUR TRUST PLAN BENEFITS Benefit Overview Express Scripts Medicare (PDP) for the Insurance Trust for Delta Retirees (ITDR) YOUR 2017 PRESCRIPTION DRUG PLAN BENEFIT Here is a summary of what you will pay
More informationThe Intersection of Valuation and Physician Productivity
The Intersection of Valuation and Physician Productivity McRae Sharpe, CMPE Shareholder August 11, 2015 Shannon W. Farr, CPA/ABV/CFF Director Objectives Define Fair Market Value (FMV) and Commercial Reasonableness
More informationWebinar Schedule. I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance
Webinar Schedule I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance II. Stakeholder Response to the 340B Ceiling Price and Manufacturer CMP Proposed Rule Thursday, Oct. 8, 2005
More informationAssociation of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations
1 Association of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations January 3, 2012 Judy Waltz, Partner Foley & Lardner LLP 2012 Foley & Lardner LLP Attorney
More informationMedicaid Price Calculations & Rebates 1.0: Mastering the Essentials
ACI Rx Drug Pricing Master Course Medicaid Price Calculations & Rebates 1.0: Mastering the Essentials November 1, 2016 William Sarraille Sidley Austin LLP Rick Zimmerer KPMG LLP Disclaimer This presentation
More informationHOSPITAL COMPLIANCE POTENTIAL IMPLICATION OF FRAUD AND ABUSE LAWS AND REGULATIONS FOR HOSPITALS
HOSPITAL COMPLIANCE H C C A R E G I O N A L C O N F E R E N C E A P R I L 2 8, 2 0 1 6 S A N J U A N, P U E R T O R I C O S A N C H E Z B E T A N C E S, S I F R E & M U Ñ O Z N O Y A, C S P J A I M E S
More information2017 PHARMACEUTICAL COMPLIANCE CONGRESS
2017 PHARMACEUTICAL COMPLIANCE CONGRESS ASSESS EMERGING RISKS AND THE ROLE FOR COMPLIANCE ACROSS MARKET ACCESS ACTIVITIES APRIL 27, 2017 PRESENTERS JANE H. YOON Of Counsel Paul Hastings LLP JACK TANSELLE
More informationAmgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract
More informationCOMMERCIAL REASONABLENESS AND FINANCIAL ARRANGEMENTS WITH PHYSICIANS
COMMERCIAL REASONABLENESS AND FINANCIAL ARRANGEMENTS WITH PHYSICIANS Daniel H. Melvin, Partner, McDermott Will & Emery, in consultation with Daryl Johnson, Managing Partner, Health Care Appraisers, Inc.
More informationA Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II
April 2017 Follow @Paul_Hastings A Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II By Gary F. Giampetruzzi & Jonathan Stevens Reproduced
More informationFraud and Abuse in the Medicare Program
Fraud and Abuse in the Medicare Program 1 / March 2009 Learning Objectives Define what fraud is and identify examples of fraud. Identify proactive measures to mitigate risk to your business or organization.
More informationAnti-Kickback Statute: Are Per-Patient Referral Fee Arrangements Permissible?
REFERRAL COMPENSATION GREGORY S. SAIK.IN/NATHANIEL C. KUMMERFELD* Anti-Kickback Statute: Are Per-Patient Referral Fee Arrangements Permissible? Federal Judge's Decision in United States v. Crinel Allows
More informationChapter 9 Medicaid and 340B
Chapter 9 Medicaid and 340B A. Introduction UPDATED 1. The complex intersection of Medicaid and 340B The intersection of 340B and Medicaid is one of the most complex and significant areas within any health
More informationFederal Spending on Brand Pharmaceuticals. April 2011
Federal Spending on Brand Pharmaceuticals April 2011 Summary Avalere Health estimates that manufacturers of brand-name prescription drugs will receive about $777 billion in revenues from the sales of outpatient
More informationCurrent Issues in Patient and Product Support. October 20, 2016
Current Issues in Patient and Product Support October 20, 2016 How Did a Perennial Issue Become the Hot Topic? 1. Reimbursement Support 2. Patient Assistance Programs 3. Donations to Charitable Foundations
More informationWhat is the 340B Program?
Emily Cook, Partner, McDermott Will & Emery Anne S. Daly, Senior Director of Compliance, Banner Health Karolyn Woo Miles, Principal, Deloitte & Touche LLP 1 What is the 340B Program? Federal drug discount
More informationMEDICARE PLAN PAYMENT GROUP
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: June 23, 2017 To: From: All Part
More informationYOUR TRUST PLAN BENEFITS
YOUR TRUST PLAN BENEFITS Benefit Overview Express Scripts Medicare (PDP) for the Insurance Trust for Delta Retirees (ITDR) YOUR 2018 PRESCRIPTION DRUG PLAN BENEFIT Here is a summary of what you will pay
More information**** CMS Regulation-Action Required****
**** CMS Regulation-Action Required**** Medicare Part D Compliance / FWA Training Annual Certification for 2017 Plan Year The Centers for Medicare & Medicaid Services (CMS) requires plan sponsors administering
More informationPHYSICIAN ALIGNMENT: LEGAL AND FAIR MARKET VALUE COMPLIANCE
PHYSICIAN ALIGNMENT: LEGAL AND FAIR MARKET VALUE COMPLIANCE Health Care Compliance Association 17 th Annual Compliance Institute April 22, 2013 Donnessa Vessakosol Strategic Value Group, LLC Cheryl Camin
More informationStructuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII
Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII The 16 th Pharmaceutical Compliance Congress and Best Practices Forum Thursday, October
More information340B Program Update & Recommendations for Monitoring Program Compliance October
340B Program Update & Recommendations for Monitoring Program Compliance October 2 2014 Speaker Biography Ray Albertina Director Deloitte & Touche LLP +1 (314) 342 4984 ralbertina@deloitte.com Ray is a
More informationGainsharing Is it Still Feasible? May 14, 2010
7 th Annual Illinois Chapter ACC Practice Management Symposium Gainsharing Is it Still Feasible? May 14, 2010 W. Kenneth Davis, Jr. Partner Katten Muchin Rosenman LLP 525 W. Monroe Chicago, Illinois 312.902.5573
More informationPharmaceutical Summit on Business and Compliance Issues in Managed Markets
Pharmaceutical Summit on Business and Compliance Issues in Managed Markets TRACK A: 340B PROGRAM CONSIDERATIONS A Panel Discussion By: Agenda Panel Introductions Overview of 340B Program Compliance Considerations
More informationThe 340B Program: Challenges and Opportunities
The 340B Program: Challenges and Opportunities March 2015 Thomas Barker Igor Gorlach Foley Hoag LLP Overview Overview and History of the 340B Program ACA s Changes to the 340B Program Recent Developments
More informationInvestigator Compensation: Motivation vs. Regulatory Compliance
Vol. 12, No. 9, September 2016 Happy Trials to You Investigator Compensation: Motivation vs. Regulatory Compliance By Payal Cramer Physician-investigators play a central role in clinical research. Through
More informationIRS relaxes bona fide residency test for individuals living in US territories
IRS relaxes bona fide residency test for individuals living in US territories Authors: Mark Strong, Senior Manager, Private Client Services, Ernst & Young LLP (McLean, VA) Ashley Weyenberg, Manager, Private
More informationIndustry Funding of Continuing Medical Education
Industry Funding of Continuing Medical Education June 25, 2010 Julie K. Taitsman, M.D., J.D. Chief Medical Officer, Office of Inspector General U.S. Department of Health and Human Services Financial Relationships
More informationImplement a definition of negotiated price to include all pharmacy price concessions.
NCPA Analysis of Medicare Part D Pharmacy DIR Fee Reform Policy Proposal and Other Policies Impacting Community Pharmacies in the CMS Proposed Rule, Modernizing Part D and Medicare Advantage to Lower Drug
More informationN R a v e n s w o o d A v e, S t e C h i c a g o, I L w w w. a e g i s - c o m p l i a n c e.
Jorge Pérez-Casellas, JD, LLM, CHC jpcasellas@aegis-compliance.com Miglisa Capó-Suria, JD, LLM mcapo@metropaviahealth.com A Presentation for the 2017 HCCA San Juan Regional Conference May 19, 2017 / 8:30AM
More informationCHANGE M MAY 30, Page 1 Page 1. CHAPTER 8 Section 9.1, pages 1 and 2 Section 9.1, pages 1 and 2
CHANGE 24 6010.60-M MAY 30, 2018 REMOVE PAGE(S) INSERT PAGE(S) FOREWORD FOREWORD Page 1 Page 1 CHAPTER 8 Section 9.1, pages 1 and 2 Section 9.1, pages 1 and 2 2 HPOB April 1, 2015 Foreword Revision: C-24,
More informationMedicare Congress: Fee for Service Trends: A Look at Medicare Part B
Medicare Congress: Fee for Service Trends: A Look at Medicare Part B November 1, 2005 Lauren Geyer Barnes Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Three
More informationNH School Health Care Coalition SCHOOLCARE 65+ January 1, Summary of Benefits
NH School Health Care Coalition SCHOOLCARE 65+ January 1, 2017 Summary of Benefits MEDICARE (PART A) - HOSPITAL SERVICES - PER BENEFIT PERIOD* *A benefit period begins on the first day you receive service
More informationM E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G
H E A L T H W E A L T H C A R E E R M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G O H I O D E P A R T M E N T O F M E D I C A I D December 6, 2016 Presenters
More informationATTN: Comments on 340B Drug Pricing Program Omnibus Guidance
October 27, 2015 Krista Pedley Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Rockville, MD 20857 ATTN: Comments on 340B Drug Pricing Program Omnibus
More informationAverage Sales Price and Medicare Part B. Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc.
Average Sales Price and Medicare Part B Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc. May, 2016 Disclaimer The views and opinions expressed in this presentation are those
More informationANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent
ANCILLARY services: How to Stay Out of Trouble Richard N.W. Wohns, M.D. JD, MBA NeoSpine, Puget Sound Region, Washington The neurosurgical minefield 2013 Informed consent HIPAA ARRA and HITECH Anti-Kickback
More informationMedicare and Patient Assistance
Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed Markets Medicare and Patient Assistance Summary AstraZeneca
More informationA. As Currently Implemented, the Recovery Purchasing Program Is Not Truly Voluntary for FSS Contractors Under Schedule 65, Part I, Section B.
April 2, 2007 Ms. Laurieann Duarte General Services Administration Regulatory Secretariat (VIR) 1800 F Street, NW Room 4035 Washington, D.C. 20405 Dear Ms. Duarte: Re: Amendment 2007-01, GSAR Case 2006-G522;
More informationRESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY
Page 1 of 6 RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY I. Purpose This document sets forth Respironics, Inc. s ( Company ) policy for engaging
More informationFlorida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter April 1, 2016 through June 30, 2016
Florida Medicaid Prescribed Drug Service Spending Control Initiatives For the Quarter April 1, through June 30, Report to the Florida Legislature December 2017 [This page intentionally left blank.] Table
More informationMedicare Part D: Retiree Drug Subsidy
A D V I S O R Y S E R V I C E S Medicare Part D: Retiree Drug Subsidy Programs to Control Fraud, Waste, and Abuse September, 2006 K P M G L L P Overview Summary Medicare Part D Prescription Drug Program
More informationPI Compensation: Methods, Documentation, and Execution
PI Compensation: Methods, Documentation, and Execution David B. Russell, CRCP Director, Site Strategy Liz Christianson Client engagement manager PFS CLINICAL 2018 PharmaSeek Financial Services, LLC d.b.a.
More informationPI Compensation: Methods, Documentation, and Execution
PI Compensation: Methods, Documentation, and Execution David B. Russell, CRCP Director, Site Strategy Liz Christianson Client engagement manager PFS CLINICAL 2018 PharmaSeek Financial Services, LLC d.b.a.
More informationTale of a Medicaid Block Grant: Notes from the Puerto Rico Health Crisis
Tale of a Medicaid Block Grant: Notes from the Puerto Rico Health Crisis Health Action Conference 2018 Families USA January 26, 2018 Boricua Medicaid Cliff 2019 (maybe 2018!!) Total of $6.3 billion increase
More informationMEDICARE PLAN PAYMENT GROUP
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: May 30, 2018 To: From: All Part D
More informationGifts to Referral Sources. Kim C. Stanger (11-17)
Gifts to Referral Sources Kim C. Stanger (11-17) Overview Some relevant laws Applying those laws to common situations Gifts to or from referral sources Gifts to physicians Gifts to or from patients Gifts
More informationPLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD 2019
PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD 2019 * A benefit period begins on the first day you receive service as an inpatient in a hospital and ends after you have been out of the hospital
More informationSteve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration
Medicaid Drug Rebates Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration Medicaid Drug Rebates History of Medicaid Drug Rebates and Preferred Drug Lists Affordable
More informationGAINSHARING & PAY FOR PERFORMANCE -- P4P UPDATE ON RECENT DEVELOPMENTS AND INITIATIVES
GAINSHARING & PAY FOR PERFORMANCE -- P4P UPDATE ON RECENT DEVELOPMENTS AND INITIATIVES presented by Robert D. Girard, Esq. Davis Wright Tremaine LLP A. Gain-Sharing B. Provider P4P programs C. Government
More informationImpact of Stark II, Phase II Regulations on Existing and Future Hospital/Physician Arrangements
Impact of Stark II, Phase II Regulations on Existing and Future Hospital/Physician Arrangements Health Care Provider Legal Issues Program WHA Annual Convention September 16, 2004 Michael Skindrud Godfrey
More informationTHIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE
THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE Donna Lee Yesner Morgan Lewis and Bockius Phone : 202.739.5887 Email: dyesner@morganlewis.com www.morganlewis.com BACKGROUND In
More informationDisclaimer. The materials and views expressed in this presentation are the views of the presenters and not necessarily the views of Northwell Health
Helpful Tips for Value Based Payment (VBP) Compliance Programs Greg Radinsky Vice President & Chief Corporate Compliance Officer Aaron Lund Director of Corporate Compliance & Privacy Officer Disclaimer
More informationThe 340B drug discount program was created in 1992
Proposed Rule Changes for 340B Programs: Overview and Impact Anthony Zappa, PharmD, MBA Specialty Healthcare Benefits Council The 340B drug discount program was created in 1992 as a means for certain nonprofit
More informationHow to Determine Commercial Reasonableness of Hospital- Physician Compensation Arrangements
How to Determine Commercial Reasonableness of Hospital- Physician Compensation Arrangements AHLA Physicians Organizations Law Institute Phoenix, AZ February 11, 2013 Presenters: Marc Goldstone, Esq. Community
More informationCheck Your Physician Contracts
Check Your Physician Contracts Publication 1/8/2014 Kim Stanger Partner 208.383.3913 Boise kcstanger@hollandhart.com Contracts and other financial arrangements with physicians and certain other healthcare
More informationFlorida Medicaid Prescribed Drug Service Spending Control Initiatives. For the Quarter July 1, 2016 through September 30, 2016
Florida Medicaid Prescribed Drug Service Spending Control Initiatives For the Quarter July 1, through September 30, Report to the Florida Legislature March 2018 [This page intentionally left blank.] Table
More informationPosition Paper on the Government Prohibition of Free Manufacturer Copayment/Financial Assistance. April 14, 2015
Position Paper on the Government Prohibition of Free Manufacturer Copayment/Financial Assistance for Patients with Government Funded Health Plans Needing Biologic or IVIG Therapies April 14, 2015 the US
More information